89bio, Inc. (ETNB) Financial Statements (2025 and earlier)

Company Profile

Business Address 655 MONTGOMERY STREET
SAN FRANCISCO, CA 94111
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

6/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:440,000,000578,900,000188,200,000150,700,000204,600,00093,335,000
Cash and cash equivalent126,060,000316,161,00055,255,00052,432,00098,183,00093,335,000
Short-term investments313,895,000262,709,000  106,446,000 
Other undisclosed cash, cash equivalents, and short-term investments45,00030,000132,945,00098,268,000(29,000) 
Restricted cash and investments    25,00025,00025,000
Prepaid expense3,945,0003,085,0002,193,0003,342,000  
Other undisclosed current assets32,505,00011,549,0005,687,0007,915,0005,577,0001,966,000
Total current assets:476,450,000593,534,000196,080,000161,982,000210,202,00095,326,000
Noncurrent Assets
Operating lease, right-of-use asset1,572,0002,293,000363,000   
Property, plant and equipment23,00046,00092,000150,000166,000155,000
Other noncurrent assets640,000396,000289,000290,000706,00072,000
Total noncurrent assets:2,235,0002,735,000744,000440,000872,000227,000
TOTAL ASSETS:478,685,000596,269,000196,824,000162,422,000211,074,00095,553,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities35,402,00029,115,00024,446,00017,037,0008,113,0005,609,000
Accounts payable15,382,0008,585,00012,502,0006,843,0002,065,000989,000
Accrued liabilities20,020,00020,530,00011,944,00010,194,0006,048,0004,620,000
Debt    2,500,000  
Other undisclosed current liabilities727,000496,000168,000   
Total current liabilities:36,129,00029,611,00024,614,00019,537,0008,113,0005,609,000
Noncurrent Liabilities
Long-term debt and lease obligation35,732,00024,795,00019,691,00016,898,000  
Long-term debt, excluding current maturities35,732,00024,795,00019,691,00016,898,000  
Liabilities, other than long-term debt6,035,0005,557,000186,000   
Other liabilities4,429,0003,740,000    
Operating lease, liability1,090,0001,817,000186,000   
Derivative instruments and hedges, liabilities 516,000     
Other undisclosed noncurrent liabilities   501,00030,000  
Total noncurrent liabilities:41,767,00030,352,00020,378,00016,928,000  
Total liabilities:77,896,00059,963,00044,992,00036,465,0008,113,0005,609,000
Equity
Equity, attributable to parent400,789,000536,306,000151,832,000125,957,000202,961,00089,944,000
Common stock120,00093,00051,00020,00020,00014,000
Additional paid in capital1,224,617,000993,455,000467,374,000339,218,000326,046,000163,526,000
Accumulated other comprehensive income (loss)563,000190,000(350,000)(64,000)(10,000) 
Accumulated deficit(824,511,000)(457,432,000)(315,243,000)(213,217,000)(123,095,000)(73,596,000)
Total equity:400,789,000536,306,000151,832,000125,957,000202,961,00089,944,000
TOTAL LIABILITIES AND EQUITY:478,685,000596,269,000196,824,000162,422,000211,074,00095,553,000

Income Statement (P&L) (USD)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating expenses(384,656,000)(151,204,000)(102,249,000)(89,743,000)(49,355,000)(26,640,000)
Operating loss:(384,656,000)(151,204,000)(102,249,000)(89,743,000)(49,355,000)(26,640,000)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
23,559,00017,676,000 (526,000)(203,000)(30,562,000)
Interest and debt expense (1,503,000)(4,794,000)(1,922,000) (230,000) 
Loss from continuing operations before equity method investments, income taxes:(362,600,000)(138,322,000)(104,171,000)(90,269,000)(49,788,000)(57,202,000)
Other undisclosed income (loss) from continuing operations before income taxes(3,787,000) 2,164,000 230,000 
Loss from continuing operations before income taxes:(366,387,000)(138,322,000)(102,007,000)(90,269,000)(49,558,000)(57,202,000)
Income tax expense (benefit)(692,000)(3,867,000)(19,000)147,00059,000(218,000)
Loss from continuing operations:(367,079,000)(142,189,000)(102,026,000)(90,122,000)(49,499,000)(57,420,000)
Loss before gain (loss) on sale of properties:(90,122,000)(49,499,000)(57,420,000)
Net loss available to common stockholders, diluted:(367,079,000)(142,189,000)(102,026,000)(90,122,000)(49,499,000)(57,420,000)

Comprehensive Income (USD)

6/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(367,079,000)(142,189,000)(102,026,000)(90,122,000)(49,499,000)(57,420,000)
Other comprehensive income (loss)373,000540,000(286,000)(54,000)(10,000) 
Comprehensive loss, net of tax, attributable to parent:(366,706,000)(141,649,000)(102,312,000)(90,176,000)(49,509,000)(57,420,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: